Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes

Abstract

Loss of Stat5a represents a new independent marker of poor prognosis in node-negative breast cancer and may be a predictor of response to antiestrogen therapy if validated in randomized clinical trials.